Study guide

16.1 Local Anesthetics, Vasoconstrictors, Dosages & Nerve Block Techniques

Saudi Dental Licensure Examination SDLE / SPLE - Dentist

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the SDLE: Format, Scoring, Eligibility, Attempts & Blueprint

2 Chapter 1: Operative Dentistry & Caries Management

1.1 Caries Etiology, Histopathology, and Risk Assessment (CAMBRA / ICDAS) 1.2 Cavity Preparation Principles and Tooth Isolation (Rubber Dam Mechanics) 1.3 Direct Composite Resin Restorations, Adhesion & Curing Dynamics 1.4 Indirect Inlays and Onlays, Minimally Invasive Restorations, Finishing and Repair

3 Chapter 2: Direct Restorations & Dental Biomaterials

2.1 Dental Amalgam Restorations, Matrix Systems & Proximal Contact Mechanics 2.2 Glass Ionomer Cements, Resin-Modified Glass Ionomers & Bioactive Materials 2.3 Dental Bonding Agents (Etch-and-Rinse vs. Self-Etch vs. Universal Systems) 2.4 Direct Pulp Capping, Indirect Pulp Capping & Pulpal Protection Liners

4 Chapter 3: Fixed Prosthodontics — Treatment Planning & Tooth Preparation

3.1 Fixed Partial Denture Treatment Planning: Abutments, Pontics and Endodontically Treated Teeth 3.2 Biological, Mechanical, and Esthetic Principles of Crown Preparations 3.3 Finish Lines and Margin Geometries (Chamfer, Shoulder, Feather-Edge) 3.4 Temporary/Provisional Restorations & Tissue Management (Gingival Retraction) 3.5 Impression Techniques, Digital Scanning & Working Casts

5 Chapter 4: Fixed Prosthodontics — Materials, Luting, Esthetics & Delivery

4.1 Dental Ceramics (Feldspathic, Lithium Disilicate, Zirconia) & Metal-Ceramics 4.2 Dental Cements and Luting Protocols (Zinc Phosphate, GI, RMGI, Resin) 4.3 Shade Selection, Color Science, and Esthetic Veneers 4.4 Fixed Prosthesis Try-In, Delivery, Complications and Repair

6 Chapter 5: Removable Partial Dentures

5.1 Removable Partial Dentures: Kennedy Classification, Rests, and Major Connectors 5.2 RPD Direct Retainers, Indirect Retainers & Surveying Principles 5.3 RPD Design Sequence, Mouth Preparation, Impressions, Try-In, Delivery and Maintenance

7 Chapter 6: Complete Dentures

6.1 Complete Denture Anatomy, Border Molding & Secondary Impressions 6.2 Maxillomandibular Relationships, Vertical Dimension & Occlusion Schemes 6.3 Complete Denture Diagnosis, Try-In, Insertion, Post-Insertion Problems and Relining

8 Chapter 7: Dental Anatomy, Occlusion & Articulators

7.1 Dental Anatomy: Tooth Notation, Permanent Tooth Morphology and Identification 7.2 Principles of Occlusion (Centric Relation, MIC, Canine Guidance, Group Function) 7.3 Articulators, Facebow Transfers & Occlusal Splints

9 Chapter 8: Basic Implantology

8.1 Basic Implantology: Patient Assessment, Treatment Planning and Implant Positioning 8.2 Implant Prosthodontics: Biomechanics, Abutment Types & Loading Protocols

10 Chapter 9: Ethics, Professionalism, Infection Control & Patient Safety

9.1 Ethics, Professionalism and Saudi Health Practice Law 9.2 Infection Control and Patient Safety in the Dental Clinic

11 Chapter 10: Periodontal Anatomy, Classification, Etiology & Pathology

10.1 Anatomy of the Periodontium and Biologic Width 10.2 2017 AAP/EFP World Workshop Classification (Staging and Grading) 10.3 Periodontal Microbiology, Host Response & Systemic Risk Factors 10.4 Applied Periodontal Pathology: Lesion Stages, Necrotizing Disease, Abscesses and Gingival Enlargement

12 Chapter 11: Periodontal Examination & Non-Surgical Therapy

11.1 Clinical Periodontal Assessment, Probing, Mobility & Furcation Involvement 11.2 Scaling and Root Planing, Ultrasonic Instrumentation & Full-Mouth Disinfection 11.3 Antimicrobial Therapy, Host Modulation & Periodontal Maintenance

13 Chapter 12: Surgical Periodontics, Peri-Implant Disease & Multidisciplinary Care

12.1 Periodontal Flap Surgery & Resective Osseous Surgery 12.2 Regenerative Periodontal Therapy (GTR, Bone Grafts, Enamel Matrix Derivatives) 12.3 Mucogingival Deformities, Soft Tissue Grafting & Peri-Implant Diseases (Mucositis vs. Peri-Implantitis) 12.4 Iatrogenic Factors, Occlusal Trauma and Multidisciplinary Periodontal Care

14 Chapter 13: Pulpal & Periapical Pathology, Diagnosis & Endodontic Treatment Planning

13.1 Pulpal Biology, Pathogenesis, and Diagnostic Terminology (AAE Classification) 13.2 Diagnostic Testing Modalities (Thermal, Electric, Percussion, Palpation, CBCT) 13.3 Endodontic Treatment Planning, Case Difficulty, Retreatment, Apical Surgery and Outcomes

15 Chapter 14: Endodontic Treatment: Anatomy, Access, Shaping & Irrigation

14.1 Internal Tooth Anatomy and Endodontic Access Cavity Preparation 14.2 Root Canal Instrumentation: Hand, Rotary, and Reciprocating Nickel-Titanium 14.3 Endodontic Irrigants (NaOCl, EDTA, CHX), Intracanal Medicaments & Smear Layer

16 Chapter 15: Obturation, Mishaps, Emergencies, Trauma & Endo-Perio Lesions

15.1 Root Canal Obturation Techniques (Cold Lateral, Warm Vertical, Bioceramic Sealers) 15.2 Management of Procedural Accidents (Ledges, Perforations, Separated Instruments) 15.3 Endodontic Emergencies, Flare-ups & Traumatic Dental Injuries (Luxations, Avulsion) 15.4 Endodontic-Periodontal Lesions, Cracked Teeth and Vertical Root Fractures

17 Chapter 16: Local Anesthesia, Surgical Principles, Biopsy & Exodontia

16.1 Local Anesthetics, Vasoconstrictors, Dosages & Nerve Block Techniques 16.2 Principles of Oral Surgery, Suturing, Wound Healing and Biopsy Techniques 16.3 Exodontia Principles, Surgical Extraction & Management of Impacted Third Molars 16.4 Post-Extraction Complications (Alveolar Osteitis, Hemorrhage, Oroantral Fistula)

18 Chapter 17: Odontogenic Infections, Maxillofacial Trauma & Dentofacial Deformities

17.1 Odontogenic Infections, Fascial Space Spread & Ludwig's Angina 17.2 Maxillofacial Trauma and Dentofacial Deformities

19 Chapter 18: Medical Emergencies & Medically Compromised Patients

18.1 Dental Office Medical Emergencies (Syncope, Anaphylaxis, Angina, Hypoglycemia) 18.2 Management of Medically Compromised Dental Patients (Cardiovascular, Anticoagulated, Diabetic) 18.3 Dental Management of Hematologic and Oncology Patients 18.4 Endocrine, Hepatic, Renal, Pulmonary, Neurological and Psychiatric Conditions in Dental Practice

20 Chapter 19: Oral Mucosal, Infectious, Immunologic & Salivary Gland Pathology

19.1 Benign and Malignant Oral Mucosal Lesions (Leukoplakia, Lichen Planus, OSCC) 19.2 Microbiological Infections of the Oral Mucosa: Fungal, Viral and Bacterial 19.3 Immunologic and Allergic Conditions, Reactive Lesions and Physical or Chemical Injuries 19.4 Salivary Gland Diseases: Obstruction, Infection, Sjögren Syndrome and Tumors

21 Chapter 20: Jaw Pathology & Abnormalities of Teeth

20.1 Odontogenic Cysts and Tumors (Radicular Cyst, Dentigerous Cyst, OKCs, Ameloblastoma) 20.2 Bone Pathology of the Jaws: Fibro-Osseous Lesions, Giant Cell Lesions, Osteomyelitis and Malignancy 20.3 Abnormalities of Teeth and Developmental Defects of the Oral Region

22 Chapter 21: Orofacial Pain, TMD & Neuromuscular Disorders

21.1 Differential Diagnosis of Odontogenic vs. Non-Odontogenic Orofacial Pain 21.2 Temporomandibular Disorders and Neuromuscular Conditions

23 Chapter 22: Orthodontic Growth, Diagnosis & Treatment Planning

22.1 Craniofacial Growth, Development & Angle's Malocclusion Classification 22.2 Cephalometric Landmarks, Analysis & Biology of Orthodontic Tooth Movement 22.3 Etiology of Malocclusion, Orthodontic Diagnosis and Treatment Planning

24 Chapter 23: Orthodontic Treatment: Interceptive, Skeletal, Canines & Fixed Appliances

23.1 Interceptive Orthodontics, Serial Extraction & Space Maintainers (Band and Loop, Nance, Lingual Arch) 23.2 Management of Class I, Class II, Class III and Skeletal Problems 23.3 Ectopic and Impacted Maxillary Canines 23.4 Fixed Appliances, Anchorage, Adult Orthodontics and Retention

25 Chapter 24: Pediatric Dentistry: Development, Behavior, Caries & Restorative Care

24.1 Dental Development, Eruption Chronology and Examination of the Child 24.2 Pediatric Behavior Guidance, Nitrous Oxide & Early Childhood Caries (ECC) 24.3 Pediatric Caries Prevention and Restorative Dentistry: Sealants, ART, Crowns and Material Choice

26 Chapter 25: Pediatric Pulp Therapy, Pain Management, Oral Surgery, Trauma & Child Protection

25.1 Pediatric Pulp Therapy (Pulpotomy vs. Pulpectomy) and Stainless Steel Crowns 25.2 Pediatric Local Anesthesia, Pain Management and Pediatric Oral Surgery 25.3 Traumatic Injuries to the Primary Dentition and Recognition of Child Abuse and Neglect

16.1 Local Anesthetics, Vasoconstrictors, Dosages & Nerve Block Techniques

Key Takeaways Explain This Topic AI

Local anesthetics block voltage-gated Na+ channels on the intracellular axoplasmic side; the uncharged free base (RN) crosses the lipophilic nerve membrane, after which the charged cation (RNH+) binds the receptor within the channel pore to halt sodium influx.

Tissue acidosis from acute infection or purulent abscess (pH ~5.0–5.5) shifts the Henderson-Hasselbalch equilibrium predominantly toward the ionized RNH+ form, leaving less than 1% as lipophilic base and causing profound local anesthesia failure.

Articaine features a thiophene ring conferring high lipid solubility and undergoes dual metabolism: 90% inactivation by plasma carboxylesterases and 10% hepatic microsomal metabolism, resulting in an ultra-short elimination half-life of 20–30 minutes.

Maximum Recommended Dose (MRD) for epinephrine is 0.2 mg in healthy individuals (~11 cartridges of 1:100,000) but strictly capped at 0.04 mg in cardiovascular patients (maximum 2 cartridges of 1:100,000 or 4 cartridges of 1:200,000).

Local Anesthetic Systemic Toxicity (LAST) progresses from initial CNS excitation (circumoral numbness, tinnitus, metallic taste, tonic-clonic seizures) to cardiovascular collapse; emergency protocol mandates 100% oxygen, airway support, midazolam for seizures, and 20% Lipid Emulsion (Intralipid) at 1.5 mL/kg IV bolus.

Last updated: October 2026

Local anesthesia represents the foundation of pain control in clinical dentistry. Achieving reliable, profound anesthesia requires a thorough understanding of the molecular pharmacology of local anesthetic molecules, the physicochemical behavior of tertiary amines in physiological and acidic tissue microenvironments, the systemic hemodynamic effects of adrenergic vasoconstrictors, and precise anatomical delivery.

  • Molecular Pharmacology and Mechanism of Action
  • Chemical Architecture: Amides vs. Esters

All clinical local anesthetic molecules share an identical fundamental tripartite molecular structure: BASIC LOCAL ANESTHETIC STRUCTURE

  • [Lipophilic Aromatic Ring] ─── [Intermediate Chain] ─── [Hydrophilic Amine]
  • (Benzene or Thiophene) (Ester or Amide) (Tertiary Amine)
  • Confers lipid solubility • Determines classification • Confers water solubility
  • Governs potency & uptake • Site of metabolic cleavage • Accepts H+ for ionization

Local anesthetics are categorized into two major chemical classes based on the linkage of their intermediate chain:

Esters ( -COO- linkage): Include procaine, tetracaine, chloroprocaine, benzocaine, and cocaine. Esters possess one "i" in their generic name (e.g., procaine). They are rapidly hydrolyzed in the bloodstream by plasma pseudocholinesterase (butyrylcholinesterase) . A primary metabolic byproduct is para-aminobenzoic acid (PABA) , a compound with high allergenic potential responsible for frequent allergic hypersensitivity reactions.

Amides ( -NHCO- linkage): Include lidocaine, articaine, mepivacaine, bupivacaine, and prilocaine. Amides possess two "i"s in their generic name (e.g., l i doca i ne, art i ca i ne). Amides are metabolized predominantly by hepatic cytochrome P450 microsomal enzymes (CYP1A2, CYP3A4), with the notable exception of articaine. True IgE-mediated allergic reactions to amides are extraordinarily rare (<1%); adverse reactions are almost universally caused by psychogenic syncope, accidental intravascular injection, or allergy to the antioxidant preservative sodium bisulfite (added to stabilize epinephrine).

Specific Receptor Theory and Sodium Channel Blockade

Local anesthetics act via the Specific Receptor Theory . Within the nerve axon, voltage-gated sodium (Na+) channels are responsible for the rapid inward sodium influx that generates action potentials during depolarization. Local anesthetics exist in solution in a dynamic chemical equilibrium between the uncharged lipophilic free base (RN) and the charged hydrophilic cationic acid (RNH+) :

RN + H + ⇌ RNH + \text{RN} + \text{H}^+ \rightleftharpoons \text{RNH}^+ RN + H + ⇌ RNH +

Membrane Translocation: The uncharged, lipophilic free base (RN) is the only form capable of penetrating the lipophilic epineurium, perineurium, and neuronal phospholipid bilayer membrane.

Receptor Binding: Once inside the relatively acidic axoplasm (pH ≈ 7.2), the free base re-equilibrates and binds hydrogen ions to reform the charged cation (RNH+).

Channel Inactivation: The charged RNH+ cation binds directly to a specific receptor site located in the inner pore/vestibule of the alpha-subunit of the voltage-gated Na+ channel. This locks the channel in an inactivated/closed conformational state, preventing sodium conductance, abolishing threshold potential attainment, and halting the propagation of impulses along the nodes of Ranvier.

Henderson-Hasselbalch Kinetics and the Acidic Tissue Dilemma

The ratio of uncharged base (RN) to charged cation (RNH+) is governed by the Henderson-Hasselbalch equation :

pH = pKa + log ⁡ ( [ RN ] [ RNH + ] ) \text{pH} = \text{pKa} + \log\left(\frac{[\text{RN}]}{[\text{RNH}^+]}\right) pH = pKa + lo g ( [ RNH + ] [ RN ] ​ )

Dissociation Constant (pKa): The pH at which exactly 50% of the local anesthetic exists as uncharged base (RN) and 50% exists as charged cation (RNH+). The pKa is the primary determinant of onset of action :

Low pKa agents (mepivacaine pKa = 7.6, articaine pKa = 7.8, lidocaine pKa = 7.9): At normal physiological tissue pH (7.4), a substantial fraction (15% to 35%) exists as uncharged RN, facilitating rapid membrane penetration and fast clinical onset (2 to 4 minutes).

High pKa agents (bupivacaine pKa = 8.1, procaine pKa = 9.1): At pH 7.4, less than 15% exists as uncharged base, resulting in a prolonged clinical onset (5 to 10 minutes).

Failure of Anesthesia in Inflamed and Infected Tissues

When local anesthetic is injected into tissue affected by acute odontogenic infection or purulent abscess, two major biological hurdles prevent adequate anesthesia:

Severe Tissue Acidosis: Purulent exudate and active tissue inflammation drive the extracellular microenvironmental pH down to 5.0 to 5.5 . Substituting this value into the Henderson-Hasselbalch equation reveals that the equilibrium shifts overwhelmingly toward the cationic RNH+ form. Less than 0.1% to 1.0% of the molecules remain as uncharged lipophilic RN. As a result, virtually no drug can penetrate the nerve sheath, leading to acute anesthetic failure.

Inflammatory Hyperemia and Neuroplasticity: Acute inflammation induces local vasodilation and increased capillary perfusion, rapidly washing the local anesthetic out of the tissue. Concurrently, inflammatory mediators (prostaglandin PGE2, bradykinin) upregulate tetrodotoxin-resistant sodium channels (Nav1.8 and Nav1.9) on nociceptive C-fibers, lowering pain thresholds and inducing peripheral sensitization.

Important

When operating in the presence of an acute periapical abscess, do not inject directly into the acidic infected tissue bed. Instead, administer a regional nerve block at an anatomically distant, uninflamed site (where normal physiological pH 7.4 permits normal membrane translocation), or utilize an intraosseous or intraligamentary injection under hydraulic pressure.

Vasoconstrictors: Receptor Pharmacology and Maximum Recommended Doses (MRD)

Adrenergic vasoconstrictors (primarily epinephrine ) are added to local anesthetic solutions to counteract the intrinsic peripheral vasodilatory properties of amide anesthetics.

Adrenergic Receptor Actions

alpha-1 Adrenergic Receptors: Located in the vascular smooth muscle of oral submucosa and skin. Stimulation causes intense local vasoconstriction, slowing systemic absorption, reducing peak plasma concentration and toxicity, prolonging the duration of pulpal and soft tissue anesthesia, and providing surgical hemostasis.

beta-1 Adrenergic Receptors: Located in cardiac myocardium and the SA/AV nodes. Stimulation increases heart rate (positive chronotropy), contractile force (positive inotropy), cardiac output, and myocardial oxygen demand, predisposing to tachyarrhythmias.

beta-2 Adrenergic Receptors: Located in skeletal muscle vascular beds. Low doses of circulating epinephrine stimulate beta-2 receptors, producing peripheral vasodilation and an initial slight dip in diastolic blood pressure. Rebound hyperemia occurs once alpha-1 stimulation wears off.

Maximum Recommended Doses (MRD) of Epinephrine

Standard dental cartridges in North America and Saudi Arabia contain 1.8 mL of solution (UK/European standard cartridges contain 2.2 mL). Epinephrine 1:100,000 equals 0.01 mg/mL (18 µg or 0.018 mg per 1.8 mL cartridge). Epinephrine 1:200,000 equals 0.005 mg/mL (9 µg or 0.009 mg per 1.8 mL cartridge). EPINEPHRINE DOSING BOUNDARIES

  • 1. HEALTHY ASA I / II PATIENT: 0.2 mg Maximum
  • 1:100,000 concentration: 0.2 mg / 0.018 mg = 11.1 cartridges
  • 1:200,000 concentration: 0.2 mg / 0.009 mg = 22.2 cartridges
  • 2. CARDIOVASCULAR / MEDICALLY COMPROMISED PATIENT: 0.04 mg Maximum
  • 1:100,000 concentration: 0.04 mg / 0.018 mg = 2.2 cartridges (STRICT MAX: 2 cartridges)
  • 1:200,000 concentration: 0.04 mg / 0.009 mg = 4.4 cartridges (STRICT MAX: 4 cartridges)

Cardiac Dose Indications: The 0.04 mg limit applies to patients with ischemic heart disease, prior myocardial infarction (>6 months), coronary artery bypass grafts, congestive heart failure (NYHA Class III/IV), significant cardiac dysrhythmias, uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg), or patients taking non-selective beta-blockers (e.g., propranolol, nadolol).

Non-Selective beta-Blocker Interaction: Co-administration of epinephrine with non-selective beta-blockers blocks compensatory beta-2 vasodilation, leaving vascular alpha-1 vasoconstriction entirely unopposed. This can precipitate a severe hypertensive crisis accompanied by compensatory reflex bradycardia.

Maximum Recommended Doses (MRD) of Dental Local Anesthetics

When calculating local anesthetic limits, the dose must be calculated based on the patient's lean body weight and capped at the absolute manufacturer maximum. The lowest threshold between the local anesthetic MRD and the vasoconstrictor MRD dictates the safe limit.

Local Anesthetic Formulation Concentration Vasoconstrictor pKa Onset Pulpal Duration Soft Tissue Duration MRD (mg/kg) Absolute Max Dose Dose per 1.8 mL Cartridge

  • Lidocaine 2% 1:100,000 Epinephrine 7.9 2–4 min 60 min 3–5 hours 7.0 mg/kg 500 mg 36 mg
  • Articaine 4% 1:100,000 Epinephrine 7.8 1–3 min 60–75 min 3–5 hours 7.0 mg/kg 500 mg 72 mg
  • Mepivacaine Plain 3% None (Plain) 7.6 1.5–2 min 20–40 min 2–3 hours 6.6 mg/kg 400 mg 54 mg
  • Bupivacaine 0.5% 1:200,000 Epinephrine 8.1 5–10 min 90–180 min 8–12 hours 1.3 mg/kg 90 mg 9 mg
  • Prilocaine 4% Plain or 1:200,000 Epi 7.9 2–4 min 40–60 min 2–4 hours 8.0 mg/kg 600 mg 72 mg
  • Clinical Distinctions and Safety Considerations

Articaine 4%: Features a thiophene ring instead of a benzene ring, conferring exceptional lipid solubility and superior bone penetration (enabling successful primary buccal infiltration for mandibular first molars). Articaine possesses a unique dual metabolic pathway: 90% is rapidly hydrolyzed by circulating plasma carboxylesterases into the inactive metabolite articainic acid, and only 10% undergoes hepatic microsomal metabolism. Consequently, its elimination half-life is extraordinarily short ( 20 to 30 minutes , compared to 90 minutes for lidocaine), significantly reducing systemic accumulation risks and making it the safest amide in patients with moderate hepatic disease.

Mepivacaine 3% Plain: Exhibits minimal intrinsic peripheral vasodilatory activity. It is the drug of choice when vasoconstrictors are contraindicated or when treating patients allergic to sulfite preservatives.

Bupivacaine 0.5%: Highly lipophilic with 95% plasma protein binding. Provides prolonged pulpal anesthesia (>1.5 to 2.5 hours) and extended soft tissue anesthesia (>8 to 12 hours), ideal for post-operative surgical pain management. Cardiotoxicity Warning: Bupivacaine dissociates very slowly from cardiac sodium channels during diastole, causing severe, refractory ventricular arrhythmias. It is strictly contraindicated in young children and mentally handicapped patients due to high rates of severe, self-inflicted soft tissue biting injuries.

Prilocaine 4% and Methemoglobinemia: Prilocaine is metabolized in the liver and lungs into ortho-toluidine (o-toluidine) . o-Toluidine is an oxidizing metabolite that oxidizes ferrous iron (Fe2+) in hemoglobin to the ferric state (Fe3+), generating methemoglobin . Methemoglobin cannot bind oxygen and causes a leftward shift of the oxygen-hemoglobin dissociation curve. Symptoms appear when methemoglobin levels exceed 10%–20%: cyanosis unresponsive to 100% oxygen, dyspnea, fatigue, headache, and classic chocolate-brown colored blood . Management: Administer the specific antidote Methylene Blue at 1 to 2 mg/kg IV of a 1% solution slowly over 5 minutes (acts as an artificial electron transporter, reducing ferric iron back to ferrous iron via NADPH-methemoglobin reductase).

Nerve Block Techniques: Anatomy, Landmarks, and Failures MANDIBULAR NERVE BLOCK COMPARISON

  • IANB (HALSTED) GOW-GATES BLOCK VAZIRANI-AKINOSI
  • Coronoid notch & raphe • Neck of condyle • Closed mouth technique
  • 6-10 mm above occlusal • Below lateral pterygoid • Maxillary MGJ level
  • Bone contact at 20-25 mm • True V3 block (~95%) • No bony contact
  • Blocks IAN, lingual, inc • Slower onset (5-10 min) • For severe trismus
  • 1. Inferior Alveolar Nerve Block (IANB / Halsted Technique)

Target: Mandibular foramen on the medial surface of the ascending ramus, deep to the lingula.

Key Anatomical Landmarks:

Coronoid notch: Deepest concavity on the anterior border of the ramus (identifies vertical height of injection).

Pterygomandibular raphe: Vertical tendon representing junction between buccinator and superior pharyngeal constrictor muscles (identifies anteroposterior boundary).

Mandibular occlusal plane: Syringe barrel is placed over the contralateral premolars , directed parallel to and 6 to 10 mm superior to the mandibular occlusal plane .

Technique and Penetration Depth: Penetrate 20 to 25 mm (two-thirds of a standard 25-gauge long needle) until gentle bony contact is established on the posterior wall of the mandibular sulcus. Withdraw 1 mm, aspirate in two planes, and deposit 1.5 mL (two-thirds to three-quarters of a cartridge) over 60 seconds to anesthetize the IAN. Withdraw the needle halfway (10 to 12 mm), re-aspirate, and deposit 0.2 to 0.3 mL (one-eighth cartridge) to anesthetize the lingual nerve .

Troubleshooting and Failure Modes:

Premature Bony Contact (<15 mm): The needle tip has contacted the internal oblique ridge or temporal crest too anteriorly. Partially withdraw the needle, swing the syringe barrel more anteriorly toward the ipsilateral mandibular canine, advance deeper to pass the bony obstruction, and reposition back over contralateral premolars.

Failure to Contact Bone (>25 mm): The needle is inserted too far posteriorly, passing behind the posterior border of the ramus directly into the parotid gland capsule . Deposition of anesthetic here causes transient unilateral facial nerve (CN VII) palsy (inability to close the ipsilateral eyelid, drooping of the labial commissure, loss of motor function; resolves spontaneously in 2 to 4 hours; requires eye lubrication and reassurance).

Accessory Innervation: Incomplete molar pulpal anesthesia despite profound lip and chin numbness is frequently caused by accessory innervation from the mylohyoid nerve (which enters accessory foramina on the lingual aspect of the mandible). Solution: Administer 0.5 mL of local anesthetic via lingual infiltration adjacent to the apex of the symptomatic molar. Other sources of failure include bifid mandibular canals, contralateral incisive nerve arborization across the midline, and branches of the cervical plexus (great auricular nerve).

2. Gow-Gates Mandibular Nerve Block

Target: Condylar neck immediately inferior to the insertion of the lateral pterygoid muscle.

Landmarks: Extraorally, an imaginary line extending from the corner of the mouth to the intertragic notch of the ear. Intraorally, the mesiolingual cusp of the maxillary second molar.

Advantages: High success rate (>95%); provides true V3 division blockade, successfully anesthetizing the IAN, lingual, mylohyoid, auriculotemporal, and mental/incisive nerves, as well as the long buccal nerve in ~75% of patients. Lowest incidence of positive intravascular aspiration (1.6% vs. 10%–15% for IANB).

Disadvantages: Slower clinical onset (5 to 10 minutes) due to large nerve trunk diameter and greater soft tissue volume; requires wide mouth opening.

3. Vazirani-Akinosi Closed-Mouth Mandibular Block

Indications: Severe trismus, temporomandibular joint ankylosis, or uncooperative patients unable to open the mouth.

Technique: Patient gently occludes teeth. Needle is advanced parallel to the maxillary occlusal plane at the level of the mucogingival junction of the maxillary second/third molars, penetrating 25 mm into the pterygomandibular space midway between the ramus and maxillary tuberosity without contacting bone.

4. Mental and Incisive Nerve Block

Target: Mental foramen located in the mucobuccal fold between the apices of the mandibular premolars.

Protocol: Deposit 0.6 to 0.9 mL outside the foramen. Apply firm digital pressure over the injection site for 2 minutes to force anesthetic solution into the mental canal, blocking the incisive nerve and providing pulpal anesthesia from the mandibular premolars to the central incisor.

5. Posterior Superior Alveolar (PSA) Block and Palatal Injections

PSA Block: Height of the mucobuccal fold above the maxillary second molar. Needle inserted 45° superiorly, 45° medially, and 45° posteriorly to a maximum depth of 16 mm . Anesthetizes the maxillary molars, with the exception of the mesiobuccal root of the maxillary first molar in ~28% of patients , which is innervated by the Middle Superior Alveolar (MSA) nerve.

PSA Hematoma Risk: Penetrating deeper than 16 mm or directing the needle too laterally lacerates the pterygoid venous plexus or maxillary artery, causing rapid, massive swelling and a disfiguring cheek hematoma. Immediate management: Firm digital pressure over the infratemporal fossa for 5 minutes, ice application, and patient reassurance.

Greater Palatine and Nasopalatine Blocks: Target the greater palatine foramen (junction of hard palate and alveolar process palatal to maxillary 2nd/3rd molars) and incisive papilla, respectively. Provide palatal soft tissue and mucoperiosteal anesthesia with zero pulpal effect.

Local Anesthetic Systemic Toxicity (LAST)

LAST is a life-threatening medical emergency caused by inadvertent rapid intravascular injection or massive absolute overdose exceeding metabolic clearance capacity. PROGRESSION OF LAST SYMPTOMATOLOGY

  • [PHASE 1: PREMONITORY CNS EXCITATION] ──┐
  • Circumoral numbness & tingling ├── Mild / Moderate Intoxication
  • Metallic taste & tinnitus (ringing) │ (Inhibitory cortical pathways blocked first)
  • Visual disturbances & agitation │
  • Muscle tremors & twitches ────────────┘
  • │
  • ▼
  • [PHASE 2: SEVERE CNS DEPRESSION] ───────┐
  • Generalized tonic-clonic seizures ├── Severe Neurotoxicity
  • Respiratory depression & apnea │ (Excitatory pathways suppressed)
  • Coma & loss of consciousness ─────────┘
  • │
  • ▼
  • [PHASE 3: CARDIOVASCULAR COLLAPSE] ─────┐
  • Severe myocardial depression ├── Fatal Cardiovascular Collapse
  • Bradycardia & conduction blocks │ (Myocardial sodium channels blocked)
  • Ventricular arrhythmias & asystole ───┘
  • Emergency Management Protocol for LAST

Stop Injection Immediately: Discontinue anesthetic administration, remove syringe, call for emergency medical assistance (Saudi 997 / 911), and note time.

Airway and Hyperoxygenation: Maintain a patent airway and administer 100% high-flow oxygen . Hyperventilate the patient to prevent hypoxia, hypercapnia, and acidosis. Acidosis drastically worsens LAST by decreasing local anesthetic protein binding and promoting intracellular ion trapping in the brain.

Seizure Management: Administer IV benzodiazepines (e.g., Midazolam 0.05 to 0.1 mg/kg IV or 5 mg IM). Avoid propofol in hemodynamically unstable patients due to worsening myocardial depression.

Targeted Antidote — 20% Lipid Emulsion (Intralipid):

Mechanism ("Lipid Sink Theory"): Intravenous infusion of a lipid emulsion creates an intravascular hydrophobic lipid compartment that sequesters lipophilic local anesthetic molecules from plasma, reversing drug binding to cardiac and cerebral tissue receptors and accelerating metabolic clearance.

Dosing Protocol:

Initial IV bolus of 1.5 mL/kg of 20% Lipid Emulsion administered over 2 to 3 minutes (~100 mL for a 70 kg adult).

Immediately initiate a continuous IV infusion of 0.25 mL/kg/min .

If hemodynamic instability persists, repeat the bolus every 3 to 5 minutes (up to a maximum total dose of 12 mL/kg) and increase the infusion rate to 0.5 mL/kg/min.

Loading diagram... Local Anesthetic Selection, Maximum Dosing, and LAST Protocol